Mixed tumors of the canine mammary glands: Evaluation of prognostic factors, treatment, and overall survival

Fernanda Camargo Nunes a, Karine Araújo Damasceno b, Cecília Bonolo de Campos e, Angélica Cavalheiro Bertagnolli d, Gleidice Eunice Lavalle e, Geovanni Dantas Cassali a,⁎

a Laboratory of Comparative Pathology, Department of General Pathology, Biological Sciences Institute (ICB), Department of General Pathology, Federal University of Minas Gerais (UFMG), Avenida Antônio Carlos 6627 Bloco C3 Sala 166 PO Box 31270-901, Pampulha, Belo Horizonte, Brazil
b Laboratory of Experimental Pathology, Gonçalo Moniz Institute, Fundação Oswaldo Cruz, Salvador, Brazil
c Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA
d Desidério Finamor Veterinary Research Institute (IPVDF), Diagnostic and Agricultural Research Department of the Department of Agriculture, Livestock and Irrigation (DDPA/SEAPI), Porto Alegre, Brazil
e Veterinary Hospital, Veterinary School, Department of Clinical and Surgical Veterinary Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil

ARTICLE INFO

Keywords:
Carcinosarcoma
Carcinoma in mixed tumor
Chemotherapy
Neoplasms

ABSTRACT

Mixed tumors are the most frequent mammary gland neoplasms in bitches; however, studies that thoroughly describe their clinicopathological data, treatment approaches, and the survival of bitches with mixed tumors are scarce. This study evaluated the epidemiological and clinicopathological data, prognostic factors, and therapeutic approaches for bitches with mixed tumors. In all, 162 benign mixed tumors, 682 carcinomas in mixed tumors, and 60 carcinosarcomas were included. Regarding tumor size, T3 lesions were predominantly associated with carcinosarcomas, while T1 and T2 lesions occurred more frequently in benign mixed tumors and in carcinomas in mixed tumors. Based on clinical staging, most bitches with benign mixed tumors presented with stage I tumors; 92% of bitches with carcinomas in mixed tumors presented with stage I–III tumors, while 8% presented with stage IV–V tumors; and 70% of bitches with carcinosarcomas presented with stage I–III tumors, while 30% presented with stage IV–V tumors. Surgery was curative for bitches with benign mixed tumors presented with stage I tumors; 92% of bitches with carcinomas in mixed tumors presented with stage I–III tumors, while 8% presented with stage IV–V tumors; and 70% of bitches with carcinosarcomas presented with stage I–III tumors, while 30% presented with stage IV–V tumors. Surgery was curative for bitches with benign mixed tumors and for those with stage I–III carcinosarcomas in mixed tumors. Combination therapy in bitches with carcinomas in mixed tumors (IV–V) and carcinosarcomas resulted in a higher overall survival compared with bitches who underwent surgery only. Carcinosarcomas presented higher relapse rates and distant metastases than carcinomas in mixed tumors did.

Introduction

Mixed tumors are the most frequent mammary gland neoplasms in bitches (Cassali et al., 2012). These tumors are characterized by epithelial, myoepithelial, and mesenchymal elements, which may undergo malignant transformation, as well as by their origins in carcinomas in mixed tumors and carcinosarcomas (Cassali et al., 2012; Misdorp et al., 1999, 2014).

Macroscopically, benign mixed tumors are characterized by benign epithelial (ductal and/or acinar cells), myoepithelial, and mesenchymal elements, along with the presence of cartilage and/or bone (Misdorp et al., 1999). Carcinomas in mixed tumors are composed of malignant epithelial and benign mesenchymal components, which may be represented by cartilage, bone, adipose tissue or all three. However, carcinosarcomas are mammary neoplasms with both malignant epithelial and mesenchymal components (Misdorp et al., 1999).

Mammary tumor prognosis is influenced by several factors including age, histological type and grade, clinical staging, tumor size, tumor biological behavior, mitotic index, regional or distant metastases, microvessel density, and molecular markers (Sorenmo, 2003; Cassali et al., 2014). Surgical treatment is the first choice for all bitches with mammary tumors (Sorenmo, 2003; Sorenmo, Worley, & Goldschmidt, 2013). Adjuvant chemotherapy is indicated for patients with regional or distant metastases and for those with mammary neoplasms with poor prognoses (Cassali et al., 2014). Combining antiangiogenic strategies and antineoplastic chemotherapeutic protocols may benefit bitches with malignant neoplasms (Pierini, Bocci, Giorgi, Owen, & Marchetti, 2012).

Studying the epidemiological and clinicopathological characteristics of mixed tumors provides important information that helps in

⁎ Corresponding author.

E-mail address: cassalig@icb.ufmg.br (G.D. Cassali).

https://doi.org/10.1016/j.vas.2018.09.003
Received 21 March 2018; Received in revised form 3 July 2018; Accepted 18 September 2018
Available online 22 September 2018
2451-943X/ © 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
understanding their biological behavior. This study evaluated the epidemiological and clinicopathological data, prognostic factors, and treatment approach in bitches with mixed tumors and is the first study to present these evaluations using a large number of cases.

Methods

All procedures were performed under the appropriate guidelines and were approved by the Ethics Committee for Animal Experimentation of the Federal University of Minas Gerais (CETEA/UFMG), protocol number 338/2012.

In total, 904 bitches were included and diagnosed with mixed tumors that were histologically classified as follows: 162 benign mixed tumors, 682 carcinomas in mixed tumors, and 60 carcinosarcomas. The histopathological classifications followed the criteria proposed by Goldschmidt, Peña, and Zappulli (2017) and were standardized per Cassali et al. (2017). All bitches were seen in the oncology department of the Veterinary Hospital of the Federal University of Minas Gerais (Universidade Federal de Minas Gerais UFMG), Brazil and received mastectomies from 2000 to 2015. The surgical technique was chosen based on the number of lesions and the lesion site, respecting lymphatic drainage and established prognostic factors, such as lesion size and presence of cutaneous or muscular adhesions, including simple mastectomy, regional mastectomy, and unilateral radical mastectomy. All the histopathological tests were performed at the Laboratory of Comparative Pathology of the UFMG Biological Sciences Institute.

Epidemiological, clinical, and pathological data were obtained from admission records. The time of tumor development was defined as the period in days from the time of perception by the owners until the time of diagnosis. All patients underwent complementary chest radiographic examinations with projections (lateral-lateral right, lateral-lateral left, and ventral-dorsal) and serum tests (complete blood count, clotting tests, and liver and kidney panels).

Staging was performed per a modified version of the original tumor, node, metastases (TNM) system established by the World Health Organization (WHO). This system enables categorizing the animals into 5 stages, as shown in Table 1 (Owen, 1980; Sorenmo et al., 2013). Next, the animals' tumors were classified during clinical staging as early (I–III) or advanced (IV–V). (Table 2).

After surgical excision, tumors were fixed in 10% buffered formalin for 48 hours, processed using routine paraffin embedding, and cut into 4-μm-thick histological sections, which were stained with hematoxylin and eosin (HE).

For histological classification, depending on tumor size, three or five fragments, representing intratumor and peripheral tumor areas were randomly selected and removed from each tumor, excluding necrotic areas (Estrela-lima et al., 2010). The tumors were graded using the Nottingham System (Elston & Ellis, 1998). Surgical excision was the initial therapeutic approach for all bitches with mammary tumors. Combination adjuvant therapy was indicated for bitches diagnosed with carcinomas in mixed tumors at advanced stages (IV–V) and bitches with carcinosarcoma regardless of stage. The proposed protocols consisted of 4 cycles of carboplatin (300 mg/m²) or carboplatin (300 mg/m²) intercalated with doxorubicin (30 mg/m²) at 21-day intervals. Following adjuvant chemotherapy, 6 months of antiangiogenic therapy was proposed with thalidomide or firocoxib (Campos et al., 2017; Lavalle, Campos, Bertagnolli, & Cassali, 2012). For patients diagnosed with distant metastases, antiangiogenic treatment was maintained without interruption.

All patients underwent clinical evaluations, chest radiography examinations, and abdominal ultrasound scans before surgery and every 3 months throughout the entire follow-up period. After surgery, the patients were followed up every 3 months during the first year and every 6 months for a minimum of 24 months. For cases in which the patient's clinical follow-up was discontinued, the owners were contacted by phone to obtain information on the animal.

Overall survival was defined as the time in days between the tumor's surgical excision and the animal's death from disease progression. Animals that died of unknown causes or causes unrelated to the tumor and those that were lost to follow-up were not included in the analysis.

Overall survival was estimated by the Kaplan–Meier curve using GraphPad Prism * v.5.0. Comparisons between groups were made using the Mantel-Cox logrank test. Comparisons between categorical variables were performed using the chi-square test, and comparisons between continuous variables were performed by an analysis of variance (ANOVA) using the statistical software, SPSS. Values were considered significant when P < 0.05.

Results

Carcinomas in mixed tumors were the most frequent, representing 75% (682/904) of cases, followed by benign mixed tumors at 18% (162/904) and carcinosarcomas at 7% (60/904).

Bitches diagnosed with benign mixed tumors were younger (mean 8.89 ± 2.69 years of age) than those with carcinomas in mixed tumors and carcinosarcomas, for which the means were 9.78 ± 2.71 and 10.50 ± 2.76 years, respectively. Bitches with benign mixed tumors had a lower mean tumor development time at diagnosis (297 days) than those with carcinomas in mixed tumors and carcinosarcomas, for which the means were 367 and 570 days, respectively.

Most bitches with mixed mammary neoplasms were purebred, intact, presented regular estrous cycles, and had never received hormones. Pseudocysts was observed in more than half the benign mixed tumor cases but was absent in most bitches with carcinomas in mixed tumors and carcinosarcomas.

The caudal and inguinal abdominal mammary glands were the most frequently affected, and approximately 70% of the benign mixed tumors, 60% of the carcinomas in mixed tumors, and 68% of the carcinosarcomas were in those glands. Regarding tumor size, most benign mixed tumors and carcinomas in mixed tumor lesions were T1 (<3.0 cm), including 76% (97/127) of benign mixed tumors and 56% (328/583) of carcinomas in mixed tumors. The next most frequent was T2 (3.0–5.0 cm), which included 14% (18/127) of benign mixed tumors and 24% (142/583) of carcinomas in mixed tumors. The least frequent was T3 (>5.0 cm), which included 9% (12/127) of benign mixed tumors and 19% (113/583) of carcinomas in mixed tumors. However, approximately 67% (32/48) of the carcinosarcomas were T1 (>3.0 cm), 23% (11/48) were T2 (3.0–5.0 cm), and 10% (5/48) were T1 (<3.0 cm).

In bitches with benign mixed tumors, stage I was the predominant clinical stage (76%; 97/127), followed by stage II (14%; 18/127), and stage III (9%; 12/127). Most of the bitches diagnosed with carcinomas in mixed tumors (92%; 540/584), presented with early stage (I–III) tumors, and evidence of metastases (IV–V) was observed in 8% (44/584) of the cases. However, in bitches with carcinosarcoma, 70% (35/50) of the cases were stage I–III, and 30% (15/50) were stage IV–V.

In patients with carcinoma in mixed tumors, stages IV–V presented lesions larger than 3.0 cm. Adherence was observed in only 2 cases of benign mixed tumors, which were both larger than 5.0 cm in diameter, and one presented ulcerated areas. Adherence and ulceration were

Table 1

| Clinical stage | Tumor size (T) | Regional lymph nodes (N) | Distant metastases (M) |
|---------------|---------------|--------------------------|------------------------|
| I             | T1            | N0,1                     | M0                     |
| II            | T2            | N0,1                     | M0                     |
| III           | T1,2,3        | N1                       | M0                     |
| IV            | T1,2,3        | N0,1                     | M1                     |
| V             | T1,2,3        | N0,1                     | M1                     |
In 35 cases of carcinomas in mixed tumors, different proliferation patterns, including aggressive histological types, were observed in association with the carcinomatous area as follows: 31% (11/35) with in situ micropapillary areas, 28% (10/35) with invasive micropapillary areas, 20% (7/35) with solid areas, 6% (2/35) with areas of apocrine metaplasia, 6% (2/35) with malignant myoepithelial areas, 6% (2/35) with tubular areas, and 3% (1/35) with sebaceous differentiation areas.

In the overall survival evaluation, bitches with carcinoma in mixed tumors with micropapillary areas and solid carcinomatous areas presented shorter survivals, with medians at 613 days and 186 days, respectively ($P = 0.0001$).

Most carcinomas in mixed tumors were histological grade I, (67%; 59/88) or grade II (29%; 26/88), while only 3.4% (3/88) were classified as grade III. However, greater frequencies of histological grades II and III (35% [6/17] and 47% [8/17], respectively) were observed in carcinosarcomas.

Bitches with benign mixed tumors and carcinomas in mixed tumors presented longer survival times but did not reach the median. However, bitches with carcinosarcomas presented a shorter overall survival with a median of 232 days ($P < 0.0001$) (Fig. 1).

In 35 cases of carcinomas in mixed tumors, different proliferation patterns, including aggressive histological types, were observed in association with the carcinomatous area as follows: 31% (11/35) with in situ micropapillary areas, 28% (10/35) with invasive micropapillary areas, 20% (7/35) with solid areas, 6% (2/35) with areas of apocrine metaplasia, 6% (2/35) with malignant myoepithelial areas, 6% (2/35) with tubular areas, and 3% (1/35) with sebaceous differentiation areas. In the overall survival evaluation, bitches with carcinoma in mixed tumors with micropapillary areas and solid carcinomatous areas presented shorter survivals, with medians at 613 days and 186 days, respectively ($P = 0.0001$).

Most carcinomas in mixed tumors were histological grade I, (67%; 59/88) or grade II (29%; 26/88), while only 3.4% (3/88) were classified as grade III. However, greater frequencies of histological grades II and III (35% [6/17] and 47% [8/17], respectively) were observed in carcinosarcomas.

Bitches with benign mixed tumors and carcinomas in mixed tumors presented longer survival times but did not reach the median. However, bitches with carcinosarcomas presented a shorter overall survival with a median of 232 days ($P < 0.0001$) (Fig. 1).

Bitches with carcinomas in mixed tumors at stages I–III presented a
longer overall survival but did not reach the median. For stages IV–V, the median was 613 days. Bitches with carcinosarcomas had a shorter overall survival, and the median survival times at stages I–III and IV–V were 338 and 78 days, respectively (P < 0.0001) (Fig. 2).

Bitches with histological grades I and II mixed malignant tumors presented longer overall survival but did not reach the median. However, evidence of histological grade III is associated with shorter survival at a median of 504 days (P = 0.0005) (Fig. 3).

All bitches with benign mixed tumors and carcinosarcomas in mixed tumors at stages I–III were treated with surgery only. In all, 37% of carcinosarcoma cases (22/60) and 32% of cases of stage IV-V carcinomas in mixed tumors (14/44) underwent adjuvant treatment.

Overall survival did not significantly differ by surgical technique (nodulectomy, simple mastectomy, regional mastectomy, or unilateral radical mastectomy (P = 0.1290)). Bitches with carcinoma in mixed tumors and carcinosarcomas with free surgical margins presented greater overall survival than did bitches with compromised surgical margins (P = 0.0010).

In bitches with stages IV and V carcinomas in mixed tumors, a median survival of 330 days was observed when surgery was the only therapeutic approach. Patients undergoing combination therapy with antineoplastic agents or antiangiogenic therapy had higher overall survival rates, of which, the median survivals were 964 and 1052 days, respectively (P = 0.0499) (Fig. 4).

Bitches with carcinosarcomas undergoing surgery presented lower overall survival rates (median, 113 days). However, when treated with adjuvant chemotherapy or adjuvant chemotherapy and antiangiogenic therapy after surgery, higher overall survival rates were observed, with medians of 414 and 664 days, respectively (P = 0.0095) (Fig. 4). (Fig. 5).

In this study, the maximum follow-up period was 5 years. The relapse rate of carcinomas in mixed tumors was 1.5% (10/682); of these, 4 cases presented clinically as inflammatory carcinoma, and 2.6% (18/682) progressed to distant metastases, with the lungs (99%; 17/18) and the brain (1%; 1/18) as the main sites. Carcinosarcoma relapses were observed in 3.3% of the cases (2/60), and 26.6% (16/268) presented distant metastases in the lungs (99%; 15/16) and liver (1%; 1/16). The mean disease-free survivals of bitches with carcinomas in mixed tumors and carcinosarcomas were 425 and 253 days, respectively.

Discussion

The mixed tumors presented high heterogeneity regarding morphological characteristics, clinical progression, and response to combination therapy. Thus, we highlight the importance of standardizing criteria for morphologically characterizing these tumors to enable differentiating the histological types of mixed tumors.

Microscopic classification of these tumors allowed predicting their prognosis and clinical progression, with benign mixed tumors and carcinomas in mixed tumors having better prognoses and longer overall survival than neoplasms of malignant epithelial and mesenchymal origin. This demonstrates the higher aggressiveness of the carcinosarcoma subtype. Methods for classifying canine mammary tumors vary considerably, making it difficult to compare studies based on the biological characteristics of malignant neoplasms (Benjamin, Lee, & Saunders, 1999; Sarli, Preziosti, Benazzi, & Marcato, 2002).

Tumor size is an independent and well-established prognostic factor in canine mammary neoplasms (Bostock, 1986; Misdorp & Hart, 1976;
Karayannopoulou et al. (2005) and Dutra, Azevedo, Schmitt, and Cassali (2009) evaluated canine mammary tumors and observed that most lesions larger than 5.0 cm (T3) were malignant, presented higher proliferation indexes, and had lower hormone receptor positivity than did smaller tumors (T1, T2).

Clinical stage was an important prognostic factor, and bitches with advanced-stage tumors exhibited worse prognoses in the overall survival analysis. Prior studies reported lower survival rates in bitches with regional lymph node metastases than did those without lymph node involvement, and worse prognoses were associated with distant metastases (Karayannopoulou, Kaldrymidou, Constantinidis, & Dessiris, 2005; Yamagami et al., 1996). Bitches with advanced-stage carcinomas in mixed tumors showed higher overall survival rates and better outcomes due to the different biological behavior and metastatic potential compared with benign mixed tumors and carcinosarcomas.

Angiogenesis has been associated with metastasis development and tumor progression in solid tumors (Raje & Anderson, 2002). This study showed that antiangiogenic therapy resulted in improved overall survival and interfered with disease progression. Angiogenesis is a crucial factor for tumor growth and for metastatic development. Lavalle, Bertagnoli, Tavares, and Cassali (2009) studied 46 mammary carcinomas in bitches found a correlation between COX-2 expression and angiogenesis as well as shorter survival. The authors suggested that using COX-2 inhibitors in these cases could be an alternative for treating and controlling advanced carcinomas in bitches.

The literature indicates that carcinosarcomas feature poor prognosis and usually result in metastases in the first 5 years after surgery (Benjamin et al., 1999), which confirms this study’s findings. Bitches with carcinomas in mixed tumors and carcinosarcomas must be evaluated periodically, for a minimum of 2 years after surgery, since the relapse rates and/or metastases in carcinosarcomas were higher than those for carcinomas in mixed tumors. Studies indicate that 50%–75% of bitches with carcinosarcomas present with lung metastases (Misdorp et al., 1973; Moulton, Rosenblatt, & Goldman, 1986). A general and specific clinical assessment must be performed every 3 months during the first year of follow-up and subsequently every 6 months. Complementary exams are important for following disease progression and investigating metastases in distant organs. Distant metastases are more commonly found in the lungs (Sorenmo, 2003; Von Euler, 2011), followed by the liver, kidneys, spleen, bones, central nervous system, and pleura (Von Euler, 2011), as observed in this study.

Here, carcinomas in mixed tumors were the most frequent neoplasms, followed by benign mixed tumors and carcinomas. Benign mixed tumors are frequent mammary gland neoplasms in bitches, and per the current veterinary classification system, they represent 40%–50% of benign tumors in canines (Cassali et al., 2014). Carcinomas in mixed tumors arise from epithelial malignant transformation in benign mixed tumors (Misdorp et al., 1999; Moulton, Taylor, & Dorn, 1970) and are the most frequent lesions, representing approximately 42%–56.7% of all malignant neoplasms of the canine mammary glands (Cassali et al., 2009; Toribio et al., 2012).

Studies indicate that benign mixed tumors affect younger bitches, aged 3 to 9 years (Bertagnoli, Ferreira, Dias, & Cassali, 2011; Cassali et al., 2012), which is similar to this study’s findings. However, malignant mammary neoplasms occur in older bitches, aged 9 to 11 years (Sorenmo et al., 2013). Misdorp et al. (1973) evaluated canine mammary carcinosarcomas and reported that the mean age for bitches diagnosed with this histological type was 11 years (range: 4–15 years), which agrees with the data in this study, as we observed advanced ages in bitches with carcinomas in mixed tumors and carcinosarcomas.

Tumor development time is a subjective tool since some owners are unaware of the precise time when spontaneous neoplasms develop in their dogs. However, a longer mean development time was observed for carcinosarcomas than for carcinomas in mixed tumors, and of these, compared with benign mixed tumors, carcinosarcomas showed a positive correlation between progression time and malignant transformation. Studies indicate that mixed tumors may undergo malignant transformation and that they primarily originate as carcinomas in mixed tumors and more rarely as carcinosarcomas and sarcomas in mixed tumors (Cassali et al., 2012; Misdorp, 1999). The prolonged time suggests that mammary neoplasms progress from benign lesions to invasive malignant lesions (Moulton et al., 1970; Sorenmo et al. 2009; Goldschmidt, Peña, Rassoto, & Zappulli, 2011). Bertagnoli et al. (2009) studying the advanced clinical stage and immunophenotypic characteristics, bitches with mammary neoplasms must undergo complementation with adjuvant chemotherapy, resulting in increased survival compared with bitches undergoing surgical excision. This agrees with the present study’s results, which showed that complementation with adjuvant chemotherapy benefited bitches with stages IV–V carcinomas in mixed tumors and for those with carcinosarcomas. Karayannopoulou et al. (2001) reported increased disease-free survival and overall survival in bitches treated with surgery and chemotherapy consisting of 5-fluoracil and cyclophosphamide compared with bitches treated with surgery only.

Surgery is the treatment of choice for all bitches with mammary tumors except those with inflammatory carcinomas (Sorenmo, 2003; Sorenmo et al., 2013). The results showed that surgery was curative for bitches with benign mixed tumors and early-stage (I–III) carcinomas in mixed tumors. Early diagnosis, in addition to an improved prognosis, allows planning conservative surgeries. Surgical margins are recommended in cases of compromised margins. Regarding combination therapy, some adjuvant protocols are suggested in the literature, and these consist of administering doxorubicin combined with cyclophosphamide, doxorubicin combined with carboplatin, carboplatin combined with gemcitabine, and paclitaxel as a single agent (Cassali et al., 2014). Per Lavalle et al. (2012), based on the advanced clinical stage and immunophenotypic characteristics, bitches with mammary neoplasms must undergo complementation with adjuvant chemotherapy, resulting in increased survival compared with bitches undergoing surgical excision. This agrees with the present study’s results, which showed that complementation with adjuvant chemotherapy benefited bitches with stages IV–V carcinomas in mixed tumors and for those with carcinosarcomas. Karayannopoulou et al. (2001) reported increased disease-free survival and overall survival in bitches treated with surgery and chemotherapy consisting of 5-fluoracil and cyclophosphamide compared with bitches treated with surgery only.
observed protein changes that may contribute to the malignant transformation of benign mixed tumors such as the loss of p63, Anp63, E-cadherin, and β-catenin expressions.

Conclusion

Carcinomas in mixed tumors are neoplasms that present good biological behavior, but depending on their epithelial histological subtypes, their prognoses may vary. However, even at advanced stages, bitches with carcinomas in mixed tumors survive longer than bitches with carcinosarcomas. Given these mixed tumors’ different biological behaviors, evaluating each patient and considering all prognostic factors are important for adopting adequate and individualized therapeutic protocols.

Acknowledgments

The authors wish to thank the Minas Gerais State Research Foundation (FAPEMIG - OET-00354-15), the Coordination for the Improvement of Higher Education Personnel (CAPES - 1783546) and the National Council for Scientific and Technological Development (CNPq - 302449/2013-2) of Brazil for financial support.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.vas.2018.09.003.

References

Benjamin, S. A., Lee, A. C., & Saunders, W. J. (1999). Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Veterinary Pathology, 36, 423–436.

Bertagnolli, A. C., Cassali, G. D., Genelhu, M. C. U. S., Costa, F. U. M. A., Oliveira, J. P. C., & Gonçalves, P. E. D. (2009). Immunohistochemical expression of p63 and neurop63 in mixed tumors of canine mammary glands and its relation with p53 expression. Vet. Pathol. 46, 407–415.

Bertagnolli, A. C., Ferreira, E., Dias, E. J., & Cassali, G. D. (2011). Canine mammary mixed tumours: Immunohistochemical expressions of EGFR and HER-2. Veterinary Pathology, 48, 117–131.

Bertagnolli, A. C., Tavares, W. L. F., & Cassali, G. D. (2009). Cox-2 expression in canine mammary carcinomas: Correlation with angiogenesis and overall survival. Veterinary Pathology, 46, 1275–1280.

Bertagnolli, A. C., Campos, G. B., Bertonelli, A. C., & Cassali, G. D. (2012). Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxgenase inhibitors. In Vivo (Athens, Greece), 26, 375–379.

Misworp, W., Cotechin, E., Hampe, J. F., Jabara, A. G., & Sandersleben, J. V. (2017). Canine malignant mammary tumors special types of carcinomas, malignant mixed tumors. Veterinary Pathology, 10, 241–256.

Misworp, W., & Hart, A. A. (1976). Prognostic factors in canine mammary cancer. Journal of the National Cancer Institute, 56, 779–786.

Misworp, W. (1999). Histological classification of the mammary tumors of the dog and the cat. In S. Series (Ed.). WHO international histological classification of tumours of domestic animals. Washington, DC: AFIP.

Moulton, J., Rosenblatt, L., & Goldman, M. (1986). Mammary tumors in a colony of beagle dogs. Veterinary Pathology, 23, 741–749.

Moulton, J. E., Taylor, D. O., & Dorn, C. R. (1970). Andersen AC. Canine mammary tumors. Pathologia Veterinaria, 7, 289–320.

Owen, L. (1980). TNM classification of tumours in domestic animals. World Health Organisation1–52.

Pierini, A., Bocci, G., Giorgi, M., Owen, H., & Marchetti, V. (2012). From humans to dogs and back: The translational lesson of metronomic chemotherapy. American Journal of Animal and Veterinary Sciences, 7, 194–1212.

Raje, N., & Anderson, K. C. (2002). Thalidomide and immunomodulatory drugs as cancer therapy. Current Opinion in Oncology, 14, 635–640.

Santos, M., Correia-Gomes, C., Marcos, R., Santos, A., De Matos, A., Lopes, C. A. G., et al. (2014). Cancer grading of the histological grading and prognosis in canine mammary carcinoma. Anticancer Research, 35, 4219–4228.

Sarli, G., Preziosi, R., Benazzi, C. G. C., & Marcato, P. S. (2002). Prognostic value of Cox-2 expression in canine mammary tumors. Veterinary and Comparative Oncology, 7, 14–23.

Sorensen, K. (2003). Canine mammary gland tumors. Veterinary Clinics of North America. Small Animal Practice, 33, 573–596.

Sorensen, K. U., Kristiansen, V. M., & Coone, M. A. (2009). Canine mammary gland tumors: a pathological continuum from benign to malignant; clinical and histopathological evidence. Vet. Comp. Oncol. 7, 162–172.

Sorensen, K. U., Worley, D., & Goldscheid, M. H. (2013). Tumors of the mammary gland. In S. J. Withrow, D. M. Vail, & R. L. Page (Eds.). Withrow and MacEwen’s small animal clinical oncology (pp. 538–556). 5th ed. St. Louis: Saunders Elsevier.

Toribio, J. M. D. M. D. M., Lima, A. E., Martinis, F. E., Ribeiro, L. G. R., Da Assis, M. J. M. H., Teixeira, R. G., et al. (2012). Clinical characterization, histopathologic diagnosis and processing of malignant tumors in bitches from the city of Salvador, Bahia State. Revista Ceres, 59, 427–433.

Von Euler, H. (2011). Tumors of the mammary gland. In J. M. Dobson, & B. Lascelles (Eds.). BSAVA Manual of canine and feline oncology (pp. 237–247). 3rd ed. Gloucester: British Small Animal Veterinary Association.

Yamagami, T., Kobayashi, T., Takahashi, K., & Sugiyama, M. (1996). Prognosis for canine malignant mammary tumors based on TNM and histologic classification. Journal of Veterinary Medical Science, 58, 1079–1083.